BioVie Yönetim

Yönetim kriter kontrolleri 4/4

BioVie CEO'su Cuong Viet Do, Apr2021 tarihinde atandı, in görev süresi 3.58 yıldır. in toplam yıllık tazminatı $ 777.08K olup, şirket hissesi ve opsiyonları dahil olmak üzere 79.5% maaş ve 20.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.51% ine doğrudan sahiptir ve bu hisseler $ 276.74K değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.5 yıl ve 6.4 yıldır.

Anahtar bilgiler

Cuong Viet Do

İcra Kurulu Başkanı

US$777.1k

Toplam tazminat

CEO maaş yüzdesi	79.5%
CEO görev süresi	3.6yrs
CEO sahipliği	0.5%
Yönetim ortalama görev süresi	3.5yrs
Yönetim Kurulu ortalama görev süresi	6.4yrs

Son yönetim güncellemeleri

Recent updates

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

Oct 14

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

Sep 06

BioVie: Four Potential Catalysts Around The Corner

Jun 07

CEO Tazminat Analizi

Cuong Viet Do'un ücretlendirmesi BioVie'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	-US$27m
Jun 30 2024	US$777k	US$618k	-US$33m
Mar 31 2024	n/a	n/a	-US$37m
Dec 31 2023	n/a	n/a	-US$43m
Sep 30 2023	n/a	n/a	-US$51m
Jun 30 2023	US$2m	US$618k	-US$50m
Mar 31 2023	n/a	n/a	-US$49m
Dec 31 2022	n/a	n/a	-US$41m
Sep 30 2022	n/a	n/a	-US$31m
Jun 30 2022	US$5m	US$300k	-US$26m
Mar 31 2022	n/a	n/a	-US$150m
Dec 31 2021	n/a	n/a	-US$145m
Sep 30 2021	n/a	n/a	-US$143m
Jun 30 2021	US$2m	n/a	-US$184m

Tazminat ve Piyasa: Cuong Viet 'ın toplam tazminatı ($USD 777.08K ) US pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 649.07K ).

Tazminat ve Kazançlar: Cuong Viet 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Cuong Viet Do (58 yo)

3.6yrs

Görev süresi

US$777,082

Tazminat

Mr. Cuong Viet Do, M.B.A, is Independent Director of Adagene Inc. from November 2022. He serves as the Founder and Chairman at M6P Therapeutics. Mr. Do serves as a Director at Seneca Therapeutics, Inc., si...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Cuong Viet Do	President	3.6yrs	US$777.08k	0.51% $ 276.7k
Joanne Kim	CFO, Treasurer & Corporate Secretary	6.1yrs	US$339.25k	0.085% $ 46.2k
Joseph Palumbo	Executive VP of R&D and Chief Medical Officer	3yrs	US$669.58k	0.11% $ 60.7k
Clarence Ahlem	Senior Vice President of Operations	less than a year	Veri yok	Veri yok
Penelope Markham	Senior Vice President of Liver Disease Program	no data	Veri yok	Veri yok
Denise Smith	Senior Vice President of Manufacturing & Development	5.8yrs	Veri yok	Veri yok
Christopher Reading	Senior Vice President of Alzheimer's Disease Program	3.3yrs	Veri yok	Veri yok

3.5yrs

Ortalama Görev Süresi

66.5yo

Ortalama Yaş

Deneyimli Yönetim: BIVI 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.5 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Cuong Viet Do	President	8.5yrs	US$777.08k	0.51% $ 276.7k
Richard Jay Berman	Independent Director	5.4yrs	US$156.01k	0.057% $ 30.7k
Sigmund Rogich	Independent Director	4.4yrs	US$127.19k	0.035% $ 18.9k
Robert Hariri	Independent Director	4.4yrs	US$127.19k	0.073% $ 39.3k
James Lang	Independent Chairman	7.9yrs	US$171.11k	0.10% $ 54.2k
Michael Sherman	Independent Director	7.3yrs	US$164.24k	0.046% $ 25.1k

6.4yrs

Ortalama Görev Süresi

65yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: BIVI 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6.4 yıldır).

BioVie Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

BioVie Inc., Annual General Meeting, Nov 07, 2024

Independent Director recently sold US$128k worth of stock

BioVie Inc., Annual General Meeting, Nov 08, 2023

Insufficient new directors

BioVie Inc., Annual General Meeting, Nov 09, 2022

Recent updates

Biovie Inc. to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long Covid At Theemystifying Long Covid International Conference

BioVie Inc.'s Upcoming Parkinson’s Disease Clinical Trial Is Fully Funded

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $3.24318 million.

BioVie Inc. has filed a Follow-on Equity Offering in the amount of $3.24318 million.

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $6.00075 million.

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $6.6645 million.

BioVie Inc. has filed a Follow-on Equity Offering in the amount of $6.6645 million.

BioVie Inc. Receives Notice of Allowance for Japan Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie Inc. Receives Notice of Allowance for United States Patent Application Covering Novel Liquid Formulation of Terlipressin

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $2.995764 million.

New major risk - Market cap size

BioVie Inc. has filed a Follow-on Equity Offering.

BioVie Inc., Annual General Meeting, Nov 07, 2024

BioVie Inc. Secures All Scientific Approvals Needed to Receive Additional $12.6 Million of Grant Funding to Launch Planned Phase 2 Trial to Evaluate Bezisterim in Long Covid

Biovie Inc. Announces Fda Authorization of Investigational New Drug Application for Phase 2 Trial to Evaluate Bezisterim in Long Covid

Biovie Inc. Announces Clinical Data Showing Epigenetic Basis for How Bezisterim May Modulate Inflammation and the Biological Aging Process At the 11Th Aging Research and Drug Discovery Meeting

BioVie Inc. Announces Alignment with FDA on Clinical Trial to Assess Bezisterim in Parkinson’S Disease

New minor risk - Share price stability

BioVie Inc. Presents Protocol Design of Upcoming SUNRISE-PD Phase 2 Trial of Bezisterim in Patients with Early Parkinson's Disease at ATMRD 2024

BioVie Inc. Announces Its Bezisterim Demonstrates Potential Improvements in Sleep/Fatigue and Restless Leg Symptoms for Parkinson’s Disease Patients

New major risk - Financial position

BioVie Awards up to $13.1 Million in Funding from U.S. Department of Defense to Evaluate Bezisterim (NE3107) for the Treatment of Long COVID

BioVie Receives Notice of Delisting from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

BioVie Receives Notice of Delisting from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2)

BioVie Inc. Announces Pipeline Update and Near-Term Clinical Priorities

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $21 million.

New major risk - Shareholder dilution

Block & Leviton LLP Files A Class Action Lawsuit Against BioVie Inc. and Certain of Its Executives, for Securities Fraud

Block & Leviton LLP Files A Class Action Lawsuit Against BioVie Inc. and Certain of Its Executives, for Securities Fraud

Independent Director recently sold US$128k worth of stock

New minor risk - Market cap size

BioVie Inc. Announces Efficacy Data from Phase 3 Trial of NE3107 in Patients with Mild to Moderate Alzheimer’s Disease

BioVie Inc. Presents Positive Clinical Safety Data from Phase 2b Trial of BIV201 in Refractory Ascites at the American Association for the Study of Liver Disease (AASLD) - The Liver Meeting® 2023

New major risk - Share price stability

BioVie Announces Late-Breaking Abstract Presenting Clinical Safety Data from the Company's Ascites Phase 2 Trial Accepted for Presentation at AASLD - The Liver Meeting®? 2023

BioVie Inc., Annual General Meeting, Nov 08, 2023

Price target increased by 11% to US$11.50

Insufficient new directors

BioVie Inc. Presents Data for NE3107 At 2023 International Congress of Parkinson’s Disease and Movement Disorders

Biovie Inc. Announces Phase 3 Trial of Ne3107 in Alzheimer's Disease

BioVie Inc. to Present Data Showing How NE3107 Potentially Regulates DNA Methylation of Specific Genes in a Manner Highly Correlated to Observed Improvements in Cognition and Biomarkers of Disease

Biovie Inc. Announces Additional Findings from Phase 2 Alzheimer’s Disease Trial: Ne3107 Appears to Impact Biomarkers of Aging-Related Disease States in Addition to Observed Reversal of Cognitive Decline in Dementia

BioVie Inc. Announces Positive Results for NE3107 in Parkinson’s and Alzheimer’s Phase 2 Trials

Biovie Inc. Phase 3 Trial Assessing Ne3107 in Alzheimer's Disease Has Fully Enrolled the Targeted 316 Patients

BioVie Inc. Phase 2 Trial Assessing Ne3107's Pro-Motoric Activity in Parkinson's Disease Is Fully Enrolled

BioVie: Recent Data In Alzheimer's Suggests +100% Upside Potential Within A Year

BioVie Inc., Annual General Meeting, Nov 09, 2022

BioVie Inc. Announces Topline Results from an Investigator-Sponsored Phase 2 Clinical Trial of NE3107 for the Treatment of Alzheimer’s Disease

BioVie: Possibly Setting Up For Success With Alzheimer's And Parkinson's Results Imminent

BioVie Inc. announced that it has received $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Inc. announced that it expects to receive $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Inc. announced that it expects to receive $6.000001 million in funding from Acuitas Group Holdings Llc

BioVie Announces Patent Issuance Covering Ascites Treatment with BIV201

BioVie: Four Potential Catalysts Around The Corner

BioVie Announces Treatment of First Patient in Phase 2 Clinical Trial of NE3107 for the Treatment of Parkinson’s Disease

BioVie Inc. Contemplates Bankruptcy

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $20 million.

Biovie Announces First Patient Enrolled in Phase 3 Study of Ne3107 in Alzheimer’s Disease

BioVie Inc. Announces First Patient Enrolled in BIV201 Phase 2b Clinical Trial for Ascites

BioVie Inc. Contemplates Bankruptcy

BioVie Commences Patient Screening in Phase 2 Clinical Trial

BioVie Inc. has completed a Follow-on Equity Offering in the amount of $15.652 million.

CEO Tazminat Analizi

CEO

Görev süresi

Tazminat

Liderlik Ekibi

Ortalama Görev Süresi

Ortalama Yaş

Yönetim Kurulu Üyeleri